SCHEMBL7103386

SCHEMBL7103386

NC(=Nc1ccccc1)N1CCCc2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.57
SMN1; SMN2 Q16637 4/20 0.55
MAPT P10636 4/20 0.54
MAPK1 P28482 1/20 0.54
NOTUM Q6P988 1/20 0.53
GAA P10253 1/20 0.52
MGLL Q99685 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.50
HTT P42858 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
POLB P06746 3/20 0.48
RECQL P46063 1/20 0.48
ALDH1A1 P00352 3/20 0.48
HPGD P15428 1/20 0.48
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6768624 0.91 SIGMAR1 (0.67) SIGMAR1SMN1; SMN2MAPTNOTUMGAA
SCHEMBL7105259 0.85 KMT2A (0.55) SIGMAR1SMN1; SMN2MAPTMAPK1NOTUM
SCHEMBL6768485 0.83 SIGMAR1 (0.51) SIGMAR1SMN1; SMN2MAPTKMT2APOLB
SCHEMBL7099090 0.83 SIGMAR1 (0.53) SIGMAR1SMN1; SMN2MAPTMAPK1NOTUM
SCHEMBL6769888 0.83 SIGMAR1 (0.53) SIGMAR1SMN1; SMN2MAPTMAPK1NOTUM
SCHEMBL6774554 0.82 SIGMAR1 (0.87) SIGMAR1SMN1; SMN2MAPTNOTUMGAA
SCHEMBL6769101 0.81 SIGMAR1 (0.52) SIGMAR1SMN1; SMN2MAPTNOTUMTDP1
SCHEMBL7098241 0.80 ATM (0.51) SIGMAR1SMN1; SMN2MAPTMAPK1NOTUM
SCHEMBL7104957 0.80 SIGMAR1 (0.50) SIGMAR1SMN1; SMN2MAPTMAPK1NOTUM
SCHEMBL7098844 0.80 SIGMAR1 (0.55) SIGMAR1SMN1; SMN2MAPTMAPK1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030153763-A1 Pharmaceutically active compounds and methods of use WYETH 2003-08-14 US claimed
US-20020099084-A1 Pharmaceutically active compounds and methods of use WYETH 2002-07-25 US claimed
EP-0925300-A4 1999-06-30 EP claimed
EP-0925300-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE CAMBRIDGE NEUROSCIENCE, INC. (US) 1999-06-30 EP claimed
WO-1997030054-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE CAMBRIDGE NEUROSCIENCE, INC. (US) 1997-08-21 WO claimed
WO-1999002145-A1 COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE, INC. (US) 1999-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153763-A1 Pharmaceutically active compounds and methods of use ACHE, PARK7, NLN SIGMAR1 2813/4885SMN1; SMN2 104/4885MAPT 122/4885
US-20020099084-A1 Pharmaceutically active compounds and methods of use ACHE, PARK7, NLN SIGMAR1 2813/4885SMN1; SMN2 104/4885MAPT 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.